Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design

Current Pharmaceutical Design

Volumn 19, Issue 28, 2013, Pages 5156-5166

  Martí Solano, Maria ^a   Guixà González, Ramon ^a   Sanz, Ferran ^a   Pastor, Manuel ^a   Selent, Jana ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Biased agonism; Drug discovery; Functional selectivity; GPCR

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ALPRENOLOL; FENOTEROL; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR STIMULATING AGENT; OXPRENOLOL; RETINA S ANTIGEN; SKF 82957; UNCLASSIFIED DRUG;

AGONIST; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; BINDING SITES; COMPUTATIONAL BIOLOGY; DRUG AGONISM; DRUG DESIGN; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84881334295     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319280014     Document Type: Review

References (106)

1. Lagerström MC, Schiöth HB. Structural diversity of G proteincoupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7(4): 339-57.
2. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5(12): 993-6.
3. Maudsley S, Martin B, Luttrell LM. The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther 2005; 314(2): 485-94.
4. Urban J, Clarke W, Von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007; 320(1): 1-13.
5. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002; 54(2): 323-74.
6. Milligan G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 2009; 158(1): 5-14.
7. Marsh D. Protein modulation of lipids, and vice-versa, in membranes. Biochim Biopshys Acta 2008; 1778(7-8): 1545-75.
8. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of α-arrestin-and G protein-biased agonists. Trends Mol Med 2011; 17(3): 126-39.
9. Smith NJ, Bennett KA, Milligan G. When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 2011; 331(2): 241-7.
10. Neubig R. Missing links: mechanisms of protean agonism. Mol Pharmacol 2007; 71(5): 1200-2.
11. Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nature reviews. Drug discovery 2012; 12(3): 205-16.
12. Galandrin S, Oligny-Longpré G, Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 2007; 28(8): 423-30.
13. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007; 28(8): 390-6.
14. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 2003; 99(1): 25-44.
15. Goupil E, Laporte SA, Hebert TE. Functional Selectivity in GPCR Signaling: Understanding the Full Spectrum of Receptor Conformations. Mini-Rev Med Chem 2012; 12: 817-30.
16. Zhang L, Brass LF, Manning DR. The Gq and G12 Families of Heterotrimeric G Proteins Report Functional Selectivity. Mol Pharmacol 2009; 75(1): 235-41.
17. Violin JD, Dewire SM, Yamashita D, et al. Selectively Engaging Beta-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance. J Pharmacol Exp Ther 2010; 335(3): 572-9.
18. Rives M-L, Rossillo M, Liu-Chen L-Y, Javitch JA. 6'GNTI is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment. J Biol Chem 2012; 287(32): 27050-4.
19. Blättermann S, Peters L, Ottersbach PA, et al. A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer. Nat Chem Biol 2012; 8(7): 631-8.
20. Rajagopal S, Kim J, Ahn S, et al. Beta-arrestin-but not G proteinmediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci USA 2010; 107(2): 628-32.
21. Park PS. Ensemble of G Protein-Coupled Receptor Active States. Curr Med Chem 2012; 19(8): 1146-54.
22. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 1980; 255(15): 7108-17.
23. Samama P, Cotecchia S. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 1993; 268(7): 4625-36.
24. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010; 62(2): 265-304.
25. Niesen MJM, Bhattacharya S, Vaidehi N. The role of conformational ensembles in ligand recognition in G-protein coupled receptors. J Am Chem Soc 2011; 133(33): 13197-204.
26. Liapakis G, Cordomi A, Pardo L. The G-protein Coupled Receptor Family: Actors with Many Faces. Curr Pharm Des 2012; 18(2): 175-85.
27. Hoffmann C, Zürn A, Bünemann M, Lohse MJ. Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open. Br J Pharmacol 2008; 153 Suppl(December 2007): S358-66.
28. Kenakin T, Christopoulos A. Analytical pharmacology: the impact of numbers on pharmacology. Trends Pharmacol Sci 2011; 32(4): 189-96.
29. Galandrin S, Bouvier M. Signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006; 70(5): 1575-84.
30. Stallaert W, Christopoulos A, Bouvier M. Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov 2011; 6(8): 811-25.
31. Kenakin TP. '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 2009; 30(9): 460-9.
32. Black J, Leff P. Operational models of pharmacological agonism. Proc R Soc London 1983; 220: 141-62.
33. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S. A simple method for quantifying functional selectivity and agonist bias. ACS Chemical Neuroscience 2012; 3(3): 193-203.
34. Rajagopal S, Ahn S, Rominger DH, et al. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 2011; 80(3): 367-77.
35. Denis C, Saulière A, Galandrin S, Sénard J-M, Galés C. Probing heterotrimeric G protein activation: applications to biased ligands. Curr Pharm Des 2012; 18(2): 128-44.
36. Lohse MJ, Nikolaev VO, Hein P, Hoffmann C, Vilardaga J-P, Bünemann M. Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. Trends Pharmacol Sci 2008; 29(3): 159-65.
37. Saulière A, Bellot M, Paris H, et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol 2012; 8(7): 622-30.
38. Charest PG, Terrillon S, Bouvier M. Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO reports 2005; 6(4): 334-40.
39. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci USA 2008; 105(29): 9988-93.
40. Christensen GL, Kelstrup CD, Lyngsø C, et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 2010; 9(7): 1540-53.
41. Xiao K, McClatchy DB, Shukla AK, et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 2007; 104(29): 12011-6.
42. González-Maeso J, Weisstaub N V, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 2007; 53(3): 439-52.
43. Stewart GD, Sexton PM, Christopoulos A. Detection of Novel Functional Selectivity at M3 Muscarinic Acetylcholine Receptors Using a Saccharomyces cerevisiae Platform. ACS Chem Biol 2010; 5(4): 365-75.
44. Ghanouni P, Gryczynski Z, Steenhuis JJ, et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. The Journal of biological chemistry 2001; 276(27): 24433-6.
45. Audet N, Galés C, Archer-Lahlou E, et al. Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing deltaopioid receptors and heterotrimeric G proteins. J Biol Chem 2008; 283(22): 15078-88.
46. Yao X, Parnot C, Deupi X, et al. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2006; 2(8): 417-22.
47. West GM, Chien EYT, Katritch V, et al. Ligand-Dependent Perturbation of the Conformational Ensemble for the GPCR 2 Adrenergic Receptor Revealed by HDX. Structure 2011; 19(10): 1424-32.
48. Zocher M, Fung JJ, Kobilka BK, Müller DJ. Ligand-Specific Interactions Modulate Kinetic, Energetic, and Mechanical Properties of the Human 2 Adrenergic Receptor. Structure 2012; 1391-402.
49. Rahmeh R, Damian M, Cottet M, et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci USA 2012; 109(17): 6733-8.
50. Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K. Biased Signaling Pathways in α2-Adrenergic Receptor Characterized by 19FNMR. Science 2012; 335(6072): 1106-10.
51. Audet M, Bouvier M. Restructuring G-Protein-Coupled Receptor Activation. Cell 2012; 151(1): 14-23.
52. Park SH, Das BB, Casagrande F, et al. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 2012; 491(7426): 779-83.
53. Scheerer P, Park J, Hildebrand P, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008; 455(7212): 2-8.
54. Rasmussen SGF, Choi H-J, Fung JJ, et al. Structure of a nanobodystabilized active state of the α(2) adrenoceptor. Nature 2011; 469(7329): 175-80.
55. Rasmussen S, DeVree B, Zou Y. Crystal structure of the α2 adrenergic receptor-Gs protein complex. Nature 2011; 477(7366): 549-55.
56. Warne T, Edwards PC, Leslie AGW, Tate CG. Crystal structures of a stabilized α1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 2012; 20(5): 841-9.
57. Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, Bouvier M. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol 2008; 74(1): 162-72.
58. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 2007; 104(42): 16657-62.
59. Wang C, Jiang Y, Ma J, et al. Structural Basis for Molecular Recognition at Serotonin Receptors. Science 2013; 340(6132): 610-14.
60. Wacker D, Wang C, Katritch V, Han G. Structural Features for Functional Selectivity at Serotonin Receptors. Science 2013; 469(7329): 175-80.
61. Granier S, Kobilka B. A new era of GPCR structural and chemical biology. Nat Chem Biol 2012; 8(8): 670-3.
62. De Graaf C, Rognan D. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. Journal of medicinal chemistry 2008; 51(16): 4978-85.
63. Katritch V, Reynolds K a, Cherezov V, et al. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. Journal of molecular recognition: JMR 2009; 22(4): 307-18.
64. Bhattacharya S, Hall SE, Li H, Vaidehi N. Ligand-Stabilized Conformational States of Human Beta2 Adrenergic Receptor: Insight into G-Protein-Coupled Receptor Activation. Biophys J 2008; 94(6): 2027-42.
65. Bhattacharya S, Vaidehi N. Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. J Am Chem Soc 2010; 132(14): 5205-14.
66. Fowler JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB. Receptor conformations involved in dopamine D2L receptor functional selectivity induced by selected transmembrane-5 serine mutations. Mol Pharmacol 2012; 81(6): 820-31.
67. Feng Z, Hou T, Li Y. Studies on the interactions between beta2 adrenergic receptor and Gs protein by molecular dynamics simulations. J Chem Inf Model 2012; 52(4): 1005-14.
68. Dror RO, Arlow DH, Maragakis P, et al. Activation mechanism of the α2-adrenergic receptor. Proc Natl Acad Sci USA 2011; 108(46): 18684-9.
69. Provasi D, Artacho MC, Negri A, Mobarec JC, Filizola M. Ligand-Induced Modulation of the Free-Energy Landscape of G Protein-Coupled Receptors Explored by Adaptive Biasing Techniques. Nussinov R, editor. PLoS Comput Biol 2011; 7(10): e1002193.
70. Goetz A, Lanig H, Gmeiner P, Clark T. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the α2-adrenergic receptor. J Mol Biol 2011; 414(4): 611-23.
71. Kim I-M, Tilley DG, Chen J, et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 2008; 105(38): 14555-60.
72. Jozwiak K, Toll L, Jimenez L, Woo AY-H, Xiao R-P, Wainer IW. The effect of stereochemistry on the thermodynamic characteristics of the binding of fenoterol stereoisomers to the beta2-adrenoceptor. Biochem Pharmacol 2010; 79(11): 1610-5.
73. Raehal KM, Bohn LM. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 2011; 60(1): 58-65.
74. Neubig R, Spedding M, Kenakin T, Christopoulos A. Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003; 55(4): 597-606.
75. Bridges TM, Lindsley CW. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol 2008; 3(9): 530-41.
76. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 2007; 28(8): 382-9.
77. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kostenis E. Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2. Mol Pharmacol 2005; 68(2): 393-402.
78. Maillet E, Pellegrini N, Valant C, et al. A novel, conformationspecific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. FASEB J 2007; 21(9): 2124-34.
79. Valant C, Maillet E, Bourguignon JJ, et al. Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration. J Med Chem 2009; 52(19): 5999-6011.
80. Burford NT, Watson J, Bertekap R, Alt A. Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 2011; 81(6): 691-702.
81. Gesty-Palmer D, Flannery P, Yuan L, et al. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Science Translational Medicine 2009; 1(1): 1ra1.
82. Allen J a., Yost JM, Setola V, et al. Discovery of beta-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proc Natl Acad Sci USA 2011; 108(45): 2-7.
83. Rocheville M, Jerman JC. 7TM pharmacology measured by labelfree: a holistic approach to cell signalling. Curr Opin Pharmacol 2009; 9(5): 643-9.
84. Fang Y, Ferrie AM. Label-free optical biosensor for ligand-directed functional selectivity acting on beta2 adrenoceptor in living cells. FEBS letters 2008; 582(5): 558-64.
85. Stallaert W, Dorn JF, Van der Westhuizen E, Audet M, Bouvier M. Impedance responses reveal αα-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PloS One 2012; 7(1): e29420.
86. Beyermann M, Heinrich N, Fechner K, et al. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain. Br J Pharmacol 2007; 151(6): 851-9.
87. Tschammer N, Bollinger S, Kenakin T, Gmeiner P. Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol 2011; 79(3): 575-85.
88. Chen X, Sassano MF, Zheng L, et al. Structure-Functional Selectivity Relationship Studies of α-Arrestin-Biased Dopamine D2 Receptor Agonists. J Med Chem 2012; 55(16): 7141-53.
89. Valant C, Aurelio L, Devine SM, et al. Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. Journal of medicinal chemistry 2012; 55(5): 2367-75.
90. Weiss DR, Ahn S, Sassano MF, et al. Conformation Guides Molecular Efficacy in Docking Screens of Activated α-2 Adrenergic G Protein Coupled Receptor. ACS chemical biology 2013
91. Seifert R, Schneider EH, Dove S, et al. Paradoxical Stimulatory Effects of the "Standard" Histamine H4-Receptor Antagonist JNJ7777120: the H4 Receptor Joins the Club of 7 Transmembrane Domain Receptors Exhibiting Functional Selectivity. Mol Pharmacol 2011; 79(4): 631-8.
92. Nijmeijer S, Vischer HF, Rosethorne EM, Charlton SJ, Leurs R. Analysis of Multiple Histamine H4 Receptor Compound Classes Uncovers Gi and α-Arrestin2 Biased Ligands. Mol Pharmacol 2012; 82(6): 1174-82.
93. Nijmeijer S, Vischer HF, Sirci F, et al. Detailed analysis of biased histamine H(4) receptor signalling by JNJ 7777120 analogues. Br J Pharmacol 2013; [ahead of print].
94. Guixa-Gonzalez R, Bruno a., Marti-Solano M, Selent J. Crosstalk within GPCR Heteromers in Schizophrenia and Parkinson's Disease: Physical or Just Functional? Curr Med Chem 2012; 19(8): 1119-34.
95. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 2008; 74(1): 59-69.
96. Strömberg I, Popoli P, Müller CE, Ferré S, Fuxe K. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci 2000; 12(11): 4033-7.
97. Rashid AJ, So CH, Kong MMC, et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 2007; 104(2): 654-9.
98. Mitchell DC, Niu SL, Litman BJ. Optimization of receptor-G protein coupling by bilayer lipid composition I: kinetics of rhodopsintransducin binding. J Biol Chem 2001; 276(46): 42801-6.
99. Niu SL, Mitchell DC, Litman BJ. Optimization of receptor-G protein coupling by bilayer lipid composition II: formation of metarhodopsin II-transducin complex. J Biol Chem 2001; 276(46): 42807-11.
100. Sadiq SK, Guixà-González R, Dainese E, Pastor M, De Fabritiis G, Selent J. Molecular Modeling and Simulation of Membrane Lipid-Mediated Effects on GPCRs. Curr Med Chem 2013; 20(1): 22-38.
101. Blanpain C, Wittamer V, Vanderwinden JM, et al. Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways. J Biol Chem 2001; 276(26): 23795-804.
102. O'Dowd B, Hnatowich M, Caron MG, Lefkowitz RJ, Bouvier M. Palmitoylation of the human beta2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor. J Biol Chem 1989; 264(13): 7564-9.
103. Reid HM, Kinsella BT. Palmitoylation of the TPbeta isoform of the human thromboxane A2 receptor. Modulation of G protein: effector coupling and modes of receptor internalization. Cell Signal 2007; 19(5): 1056-70.
104. Ballesteros J, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 1995; 25: 366-428.
105. Woo AY, Wang T, Zeng X, et al. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol 2009; 75(1): 158-65.
106. Ryman-Rasmussen J, Nichols D, Mailman RB. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol 2005; 68(4): 1039-48.